CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 6,609 enrolled
Drug / intervention
Empagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03594110
NCT03594110Phase 3Completed
CompareCT.gov

A Multicentre International Randomized Parallel Group Double-blind Placebo-controlled Clinical Trial of EMPAgliflozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic KIDNEY Disease

Boehringer Ingelheim·interventional·Posted Jul 20, 2018·Updated Jul 20, 2025

In Brief

A Phase 3 clinical trial evaluating Empagliflozin and Matching placebo for Chronic Kidney Disease. Completed, enrolled 6,609 participants across 240 sites in 8 countries.

Detailed Summary

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease. After completion of the interventional part of the study (primary study completion) a subset of participants will be followed up in a post-trial observational (non-interventional) manner for cardio-renal outcomes (estimated study completion date).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesCanada, China, Germany, Italy, Japan, Malaysia, United Kingdom, United States
CollaboratorsUniversity of Oxford, Eli Lilly and Company

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 20, 2018
Enrollment StartJan 31, 2019
Primary CompletionJul 5, 2022
Study CompletionJul 2, 2024
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.0 years ago

Interventions

Empagliflozindrug

Taken daily with or without food

Matching placebodrug

Taken daily with or without food